Introduction
============

Lymphoid malignancies are a diverse group of neoplasms with different clinical presentations, histology, and biology. They are classified by the morphology, immunophenotype, cytogenetics, and clinical characteristics. The etiology of lymphoid neoplasms is not fully understood. Thus, combining an epidemiologic study with a biological study is helpful for understanding the pathogenesis of each disease.

Different incidences of lymphoid malignancies between regions have been reported \[[@b1-crt-2017-093]\]. Asian countries have been known to show a relatively lower incidence than the other countries in North America and Europe. In terms of the subtypes of lymphoid malignancies, it also varies in each region. For example, Asian populations show a higher incidence of mature T/natural killer (NK)--cell lymphoma and extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (mucosa-associated lymphoid tissue lymphoma), in contrast, Western population show higher incidence of follicular lymphoma and chronic lymphocytic leukemia (CLL) \[[@b2-crt-2017-093],[@b3-crt-2017-093]\]. The distribution of lymphoma-associated viruses such as Epstein-Barr virus and human T-lymphoblastic virus-1 has been proposed as a risk factor for the high incidence of specific subtypes of mature T/NK-cell lymphoma in Asian people, but genetic factors may also affect the incidence \[[@b4-crt-2017-093],[@b5-crt-2017-093]\].

The classification of hematologic malignancies mainly focused on morphologic and immunophenotypic characteristics before 1990s \[[@b6-crt-2017-093]-[@b8-crt-2017-093]\], but it has been modified to include cytogenetic characteristics which provide an improved understanding of tumor pathogenesis. The most recent classification of diseases for oncology, International Classification of Diseases for Oncology, third edition (ICD-O-3) was published in 2000 \[[@b9-crt-2017-093]\] and updated in 2013 to include the changes from the World Health Organization (WHO) classification published in 2008 \[[@b2-crt-2017-093]\]. Recent cancer registry studies have adopted this ICD-O-3, because it more accurately reflects our recent understanding of these diseases \[[@b10-crt-2017-093],[@b11-crt-2017-093]\].

We have published nationwide statistical analyses of hematologic malignancies based on the Korea Central Cancer Registry (KCCR) in 2012 \[[@b12-crt-2017-093]\]. However, the data was not based on the ICD-O-3 classification. Therefore, to understand the comprehensive incidence and survival of lymphoid malignancies in Korea, we conducted present study with available ICD-O-3 data from the KCCR.

Materials and Methods
=====================

The Korean Ministry of Health and Welfare started the KCCR, a nationwide hospital-based cancer registry in 1980. In 1999, the KCCR expanded to include the entire population in the population-based cancer registry program. Incidence data on lymphoid malignancies between 1999 and 2012 was obtained from the Korean National Cancer Incidence Database (KNCIDB).

The classification of lymphoid malignancies was categorized to account for incidence and clinical characteristics based on the ICD-O-3 \[[@b9-crt-2017-093]\]. The codes for lymphoid malignancies were grouped into five clinically relevant categories based on the 2008 WHO classification \[[@b2-crt-2017-093]\]: Hodgkin's lymphoma (HL), mature B-cell neoplasms, mature T-cell and NK-cell neoplasm, precursor cell neoplasm, and unknown type of lymphoid neoplasm ([S1 Table](#SD1-crt-2017-093){ref-type="supplementary-material"}).

The crude incidence rates (CR) and age-specific incidence rates of each subtype of lymphoid malignancy were calculated. The CR per 100,000 persons was calculated as an incidence rate based on the frequency of the disease in the entire population by dividing the total number of events (*N*) by the total number of person-year of observation (*P*) and multiplying the result by 100,000. The age-specific incidence rates per 100,000 within an age group (*i*) were calculated by dividing the number of incident cases observed in the age group (*N~i~*) by the number of corresponding person-year of observation (*P~i~*) and multiplying the result by 100,000. Age-standardized incidence rates (ASRs), a weighted average of crude age-specific rates, were calculated using the Segi's world standard population \[[@b13-crt-2017-093]\]. Changes in the annual ASRs were examined by calculating the annual percentage change (APC) over a time period as (exp(b)--1)×100, where b is the slope of the regression of log(ASR) on a calendar year using the following linear regression equation: E(log(ASR)\|year)=a+b year \[[@b14-crt-2017-093]\].

For the survival analyses, cases that were diagnosed as lymphoid malignancies and have available data in the KNCIDB between 1993 and 2012 were included. The patient status was followed until December 31, 2013. The relative survival rate (RSR) was estimated by comparing the observed survival of cancer patients with the expected survival of the general population \[[@b15-crt-2017-093]\]. Five-year RSR was calculated based on the Ederer II method using the algorithm created by Paul Dickman in SAS \[[@b16-crt-2017-093],[@b17-crt-2017-093]\]. All analyses were performed using SAS ver. 9.2 (SAS Institute Inc., Cary, NC).

Results
=======

1. Incidences of lymphoid malignancies in 2012
----------------------------------------------

A total of 10,409 cases of hematologic malignancies occurred in 2012, including 6,638 lymphoid malignancies (63.8%) (3,732 men and 2,906 women, male:female ratio=1.28:1) ([Fig. 1](#f1-crt-2017-093){ref-type="fig"}). This means that the proportions of lymphoid malignancy were 3.3% and 2.6% of all cancers in men and women, respectively. Among all lymphoid malignancies in men, mature B-cell neoplasms (71.8%) were the most frequent, followed by mature T-cell and NK-cell neoplasms (10.5%), and precursor cell neoplasms (8.7%). In women, mature B-cell neoplasms (74.5%) were the most frequent, followed by precursor cell neoplasms (8.8%), and mature T-cell and NK-cell neoplasms (8.4%).

Patients with aged between 70 and 79 years the highest incidence of lymphoid malignancies in 2012, followed by those aged 50 to 59 years, and then 60 to 69 years ([Fig. 2](#f2-crt-2017-093){ref-type="fig"}). The precursor cell neoplasms were the most prevalent disease type in patients aged group 0-19 years, whereas mature B-cell neoplasms were the most prevalent in those aged more than 20 years.

2. Changes in incidences of lymphoid malignancies between 1999 and 2012
-----------------------------------------------------------------------

The incident cases of each subtype of lymphoid malignancies and trends in CR and ASR between 1999 and 2012 are shown in [Table 1](#t1-crt-2017-093){ref-type="table"}. During the study period, 65,948 lymphoid malignancies were registered. The overall ASR of all lymphoid malignancies increased from 6.9 to 9.9 during the study period. The APC was 3.2% between 1999 and 2012, and it was statistically significant. The ASRs increased from 0.24 to 0.46 in HL (APC, 5.0%; p \< 0.05), from 3.41 to 6.60 in mature B-cell neoplasm (APC, 5.6%; p \< 0.05), from 0.47 to 0.95 in mature T-cell and NK-cell neoplasm (APC, 6.6%; p \< 0.05), and from 1.33 to 1.50 in precursor cell neoplasm (APC, 1.4%; p \< 0.05). The ASR of cases categorized as "unknown type lymphoid neoplasm" decreased from 1.44 to 0.41 (APC, --9.3%; p \< 0.05).

3. Estimated RSRs of lymphoid malignancies
------------------------------------------

The 5-year RSRs of patients with lymphoid malignancies in 5-year intervals (1993-1997, 1998-2002, 2003-2007, and 2008-2012) are shown in [Table 2](#t2-crt-2017-093){ref-type="table"}. HL was associated with better survival than the other disease categories. Decreasing survival with age was observed in most disease types of lymphoid malignancies, with poor prognoses in elderly patients. Especially in patients with precursor cell neoplasms, abrupt decrease in survival rates were observed between pediatric patients (aged 0-14 years), adolescents and young adults (aged 15-34 years), and adults (aged 35 years or more).

4. Changes in the RSRs by major subtypes
----------------------------------------

The 5-year RSRs of patients with lymphoid malignancies continually increased from 1993 to 2012, from 45.3% to 61.7%, with an increment of 16.4% between these years. The 5-year RSR for most lymphoid malignancies was improved: from 71.1% to 83.0% in HL, from 42.8% to 63.8% in mature B-cell neoplasms, and from 41.5% to 56.3% in precursor cell neoplasms.

Trends in the RSRs of several major subtypes that are clinically important and accessible in our database are shown in [Fig. 3](#f3-crt-2017-093){ref-type="fig"}. Yearly improvement of survival outcome was observed in HL, diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), lymphoblastic lymphoma, and acute lymphoblastic leukemia. However, survival improvement was not evident in peripheral T-cell lymphomas or extranodal NK/T-cell lymphomas between 1993 and 2012.

Discussion
==========

Here, we presented the first comprehensive epidemiologic analysis for lymphoid malignancies in the Korean population. The incidence of lymphoid malignancies increased yearly between 1999 and 2012. In most subtypes except precursor cell neoplasms, the incidences in adults and elderly patients were higher than those in pediatric patients. Relative survival improved during the study period in lymphoid malignancies. However, poor survival outcomes in elderly patients were observed in most subtypes except in indolent diseases such as marginal zone lymphoma.

The incidence of most subtypes in Korea was low, with an ASR less than one per 100,000 except for DLBCL (2.34) and plasma cell neoplasms (1.30). This incidence is quite low compared to data from other countries as we expected based on previous reports of differences in incidences of lymphoid malignancies between countries or ethnic groups ([Table 3](#t3-crt-2017-093){ref-type="table"}) \[[@b11-crt-2017-093],[@b14-crt-2017-093],[@b18-crt-2017-093],[@b19-crt-2017-093]\]. The incidence of several subtypes, including follicular lymphoma (ASR, 0.18) and CLL (ASR, 0.18), is lower in Korea than in Western countries. In contrast, the incidence of extranodal NK/T-cell lymphoma, nasal type was relatively high (ASR, 0.22). CLL/small lymphocytic lymphoma (SLL) is the second most common subtype of mature B-cell malignancies in Europe (26%); however, it is rare in Korea (3.4%). Follicular lymphoma was also rare in Korea compared to in European countries (3.4% vs. 11% of mature B-cell malignancies) \[[@b11-crt-2017-093]\]. The proportions of CLL/SLL and follicular lymphoma among B-cell non-Hodgkin's lymphoma (NHL) in the United States were 19.6% and 12.3%, respectively \[[@b14-crt-2017-093]\]. Although we cannot directly compare the ASRs from our data with those of other registry-based incidences, there are subtype-specific differences in the Korean population compared to foreign data. An increasing trend in the incidence of HL and NHL was observed in Korea, which is similar to Japan \[[@b19-crt-2017-093]\], but not the United States.

Comprehensive subtype-specific analysis in Asia is limited so far. A recent study performed in Hong Kong showed differences between Hong Kong and the United States \[[@b18-crt-2017-093]\]. The authors compared the incidences of lymphoid malignancies between the East Asian and white populations from Surveillance, Epidemiology, and End Results (SEER) data, and found that the age-adjusted incidence of most subtypes was \< 1 per 100,000 in the Hong Kong population, except for DLBCL (3.26) and plasma cell neoplasms (1.99). The incidences of follicular lymphoma and CLL were 0.75 and 0.52, respectively, which was quite high compared to the incidences in our data (0.18 and 0.18). Rates in Asians from SEER data were generally intermediate compared to the rates in SEER Whites. Similar to our data, the incidence of extranodal T/NK-cell lymphoma, nasal type was much higher in Hong Kong (0.25) than in the United States (SEER White) (0.06). However, the number of Asian population in this analysis was relatively small compared to our data, with fewer than 10,000 cases in the Asian group, and survival data were lacking.

To our knowledge, this is the first population-based and subtype-specific survival analysis of hematologic malignancies in Asia. Comprehensive analysis based on subtypes defined by ICD-O-3 code is more useful than past population-based studies that divided lymphoid diseases in to broad categories such as 'non-Hodgkin's lymphoma' or 'leukemia' \[[@b20-crt-2017-093]\].

The multicenter retrospective analysis in Korea by Won et al. \[[@b21-crt-2017-093]\] previously showed that the overall survival rate of classical HL with a median follow-up of 30 months was 80.2%. It did not include pediatric patients under the age of 16 years. In our KCCR data, the 5-year survival rate was 82.7% in 2008-2012. The overall survival outcome of HL was favorable. However, the survival rate of elderly patients over 65 years significantly decreased to 37%-54.4%. The poor outcome of elderly patients may be due to unfavorable tumor biology and underlying comorbidities as well as the toxicity of current standard chemotherapy such as anthracyclines and bleomycin \[[@b22-crt-2017-093],[@b23-crt-2017-093]\]. The introduction of less toxic but effective treatment would likely improve survival outcomes, especially in elderly patients, and the results of such treatment regimens could be evaluated in a future update of KCCR analyses.

We also observed marked survival improvement in patients with DLBCL between the pre-rituximab and post-rituximab era: 5-year RSRs of 49.5% to 61.5% from 1993-1997 to 2008-2012, respectively. Rituximab, a monoclonal antibody that binds to CD20 on B cells and induces apoptosis of lymphoma cells, was approved in November 2003 by the Ministry of Food and Drug Safety (MFDS) in Korea. The influence of rituximab-containing chemoimmunotherapy on DLBCL survival has been reported \[[@b24-crt-2017-093]\]. In addition, rituximab has been approved for various indications in NHLs other than DLBCL in the United States \[[@b25-crt-2017-093]\]. In our data, survival rates of follicular lymphoma also increased during the study period. With the broadened indication of rituximab in Korea for other NHLs such as mantle cell lymphoma and marginal zone lymphoma, we can expect better outcomes in the future data, although there were no significant improvements of survival in the present data.

For other T- and NK-cell lymphomas, except cutaneous T-cell lymphoma, there were no evident changes in survival rates during the study period (5-year RSR, 44.2% to 44.2% between 1993-1997 and 2008-2012, respectively). This result is in line with the unsatisfactory results of clinical trials for the disease categories, except for the paradigm shift in the management of extranodal NK/T-cell lymphoma, nasal type. In localized diseases, concomitant/sequential chemo

therapy and radiotherapy became standard therapy because radiotherapy alone was not adequate due to systemic relapse \[[@b26-crt-2017-093]\]. For advanced cases, systemic chemotherapy containing L-asparaginase and drugs unaffected by P-glycoprotein was indicated \[[@b27-crt-2017-093]\]. In subtype-specific analyses, survival of extranodal NK/T-cell lymphoma, nasal type, improved, revealing a 5-year RSR of 49.9% for all age groups in 2008-2012 (n=869) compared to 45.8% in 2003-2007 (n=670) and 46.5% in 1998-2002 (n=314) ([Fig. 3](#f3-crt-2017-093){ref-type="fig"}). The RSR in 1993-1997 seems to be superior, but this result might be due to a limitation of the registry; the registry did not cover the entire population at that time, so the number of cases was relatively insufficient (153 cases in 1993-1997). The survival benefits from the current therapy for extranodal NK/T-cell lymphoma, nasal type, needs to be confirmed in future analysis.

The standard treatment of MM also changed during the study period. Autologous stem cell transplantation was introduced in early 1990s. In addition, thalidomide, bortezomib, and lenalidomide were approved by MFDS in April 2006, March 2006, and December 2009, respectively. We found that the 5-year RSR of patients with plasma cell neoplasms changed from 20.2% to 36.9% from 1993 to 2012, respectively. This rate is still unsatisfactory, and it is lower than the RSR in the United States (48.5%) between 2006 and 2012 \[[@b14-crt-2017-093]\], but an increasing trend in survival rates in Korea is encouraging for such an 'incurable disease.'

The survival rates of acute lymphoblastic leukemia/lymphoma showed improving trends based on the year of diagnosis, with 5-year RSR of all age groups reaching 56.3% in 2008-2012. Age at diagnosis significantly influenced the survival of this disease. The 5-year RSR in pediatric patients (aged 0-14 years) is 82.7%, but it falls dramatically in young adults (50.1%, aged 15-34 years) and adults (33%, aged 35-49 years). Poor prognosis of adult acute lymphoblastic leukemia /lymphoma is historically well known, and the factors associated with this difference in outcome include the poorer biology of the leukemia, the lower compliance of patients (physically and emotionally), differences in the therapeutic approaches, and the lower rates of enrollment in clinical trials \[[@b28-crt-2017-093]-[@b30-crt-2017-093]\]. Efforts to improve outcomes in adults include development of pediatric-inspired chemotherapy protocols for young adults and the combination of tyrosine kinase inhibitors, such as imatinib and dasatinib with conventional chemotherapy for Philadelphia-positive disease. Well-designed and clinical trial-based treatment protocols for adult patients should be established in Korea.

We reported the subtype-specific incidence and survival of lymphoid malignancies. Our research showed increasing incidence and survival rates based on the year of diagnosis in most subtypes. In addition, the survival rates of most subtypes (except for indolent disease) decreased dramatically with age. The strength of our study is that these data were analyzed in clinically meaningful disease categories. Additionally, this is a good example for refining and utilizing data from pre-existing cancer registry. If we can integrate more detailed information such as immunophenotypes, genetic abnormalities, and treatment information, to the registry, the quality of data on hematologic malignancies will improve. The qualified registry can provide practical evidence to determine whether advances in diagnosis and treatment can improve cancer survival.
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![Incident cases of lymphoid malignancies in Korea, 2012. NK, natural killer; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; MPN, myeloproliferative neoplasm. ^a)^Include one case of composite Hodgkin's and non-Hodgkin's lymphoma.](crt-2017-093f1){#f1-crt-2017-093}

![Incident cases of lymphoid malignancies by age group in Korea, 2012. NK, natural killer. ^a)^All lymphoid malignancies include one case of composite Hodgkin's and non-Hodgkin's lymphoma.](crt-2017-093f2){#f2-crt-2017-093}

![Trend in relative survival rate of lymphoid malignances between 1993 and 2012 in Korea. ICD-O-3 codes are as follows. (A) Hodgkin's lymphoma 9659, 9650, 9661, 9662, 9651, 9663, 9664, 9665, 9667, 9652,9653, 9654, 9655. (B) Diffuse large B-cell lymphoma 9675, 9678, 9679, 9680, 96849684. (C) Multiple myeloma 9732. (D) Peripheral T-cell lymphoma, except NK/ T-cell lymphoma 9702, 9705, 9714, 9716, 9717. (E) Extranodal NK/T-cell lymphoma, nasal type 9719. (F) Lymphoblastic lymphoma 9728, 9729, 9727. (G) Acute lymphoblastic leukemia 9836, 9837, 9835. (H) All lymphoid malignancies. ICD-O-3, International Classification of Diseases for Oncology, third edition.](crt-2017-093f3){#f3-crt-2017-093}

###### 

Number of lymphoid malignancies and trend in crude incidence rates and age-standardized incidence rates

  Site                                                               Total    Year    APC                                                                                                     
  ---------------------------------------------------------- ------- -------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------------------------------------------------------
  **Hodgkin's lymphoma**                                     Cases   2,651    119     133     147     143     158     204     157     176     204     217     220     247     262     264     
                                                             CR      0.39     0.25    0.28    0.31    0.30    0.33    0.42    0.32    0.36    0.42    0.44    0.44    0.50    0.52    0.52    
                                                             ASR     0.35     0.24    0.26    0.29    0.28    0.30    0.39    0.29    0.34    0.37    0.40    0.39    0.43    0.48    0.46    5.0^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Hodgkin's lymphoma, nodular lymphocyte predominant        Cases   62       \< 5    \< 5    \< 5    \< 5    5       \< 5    \< 5    \< 5    \< 5    \< 5    8       9       6       5       
                                                             CR      0.01     0.01    0.01    0.01    0.01    0.01    0.00    0.01    0.01    0.01    0.00    0.02    0.02    0.01    0.01    
                                                             ASR     0.01     0.01    0.01    0.01    0.01    0.01    0.00    0.01    0.01    0.01    0.00    0.01    0.02    0.01    0.01    4.1
   Classical Hodgkin's lymphoma                              Cases   2,589    115     130     143     140     153     202     154     172     200     215     212     238     256     259     
                                                             CR      0.38     0.24    0.27    0.30    0.29    0.32    0.42    0.32    0.35    0.41    0.44    0.43    0.48    0.51    0.51    
                                                             ASR     0.34     0.23    0.26    0.28    0.28    0.29    0.39    0.29    0.33    0.37    0.40    0.38    0.41    0.47    0.45    5.0^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
  **Mature B-cell neoplasms**                                Cases   42,647   1,650   1,613   1,895   2,044   2,425   2,663   2,877   3,088   3,323   3,575   4,024   4,154   4,472   4,844   
                                                             CR      6.24     3.50    3.39    3.96    4.25    5.02    5.49    5.91    6.32    6.76    7.24    8.10    8.33    8.92    9.62    
                                                             ASR     5.09     3.41    3.26    3.71    3.89    4.46    4.76    4.95    5.16    5.34    5.55    6.01    6.05    6.30    6.60    5.6^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Chronic lymphocytic leukemia/Small lymphocytic lymphoma   Cases   1,495    90      65      87      103     81      102     89      126     102     104     126     116     147     157     
                                                             CR      0.22     0.19    0.14    0.18    0.21    0.17    0.21    0.18    0.26    0.21    0.21    0.25    0.23    0.29    0.31    
                                                             ASR     0.18     0.19    0.13    0.17    0.20    0.15    0.18    0.15    0.20    0.16    0.16    0.18    0.16    0.20    0.20    1.0
   Immunoproliferative diseases                              Cases   310      7       8       20      16      14      15      20      20      27      30      32      27      36      38      
                                                             CR      0.05     0.01    0.02    0.04    0.03    0.03    0.03    0.04    0.04    0.05    0.06    0.06    0.05    0.07    0.08    
                                                             ASR     0.04     0.01    0.02    0.04    0.03    0.03    0.03    0.03    0.03    0.04    0.05    0.05    0.04    0.05    0.05    8.0^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Mantle cell lymphoma                                      Cases   734      27      22      32      22      36      50      48      67      50      68      58      80      70      104     
                                                             CR      0.11     0.06    0.05    0.07    0.05    0.07    0.10    0.10    0.14    0.10    0.14    0.12    0.16    0.14    0.21    
                                                             ASR     0.09     0.06    0.04    0.06    0.04    0.07    0.09    0.08    0.11    0.08    0.10    0.08    0.11    0.09    0.13    7.1^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Follicular lymphoma                                       Cases   1,498    76      57      74      89      92      77      69      102     107     124     128     132     175     196     
                                                             CR      0.22     0.16    0.12    0.15    0.18    0.19    0.16    0.14    0.21    0.22    0.25    0.26    0.26    0.35    0.39    
                                                             ASR     0.18     0.16    0.11    0.14    0.16    0.17    0.13    0.12    0.17    0.18    0.20    0.19    0.19    0.25    0.28    5.1^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Diffuse large B-cell lymphoma                             Cases   19,659   856     872     988     997     1,154   1,287   1,320   1,395   1,545   1,613   1,758   1,821   2,003   2,050   
                                                             CR      2.88     1.81    1.83    2.06    2.07    2.39    2.65    2.71    2.85    3.14    3.26    3.54    3.65    4.00    4.07    
                                                             ASR     2.34     1.75    1.74    1.92    1.88    2.10    2.29    2.27    2.32    2.47    2.50    2.63    2.65    2.82    2.77    4.0^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Burkitt's lymphoma/Leukemia                               Cases   976      25      32      30      63      58      75      61      85      92      82      83      92      92      106     
                                                             CR      0.14     0.05    0.07    0.06    0.13    0.12    0.15    0.13    0.17    0.19    0.17    0.17    0.18    0.18    0.21    
                                                             ASR     0.16     0.06    0.09    0.08    0.16    0.14    0.18    0.14    0.19    0.20    0.18    0.20    0.23    0.21    0.25    9.6^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Marginal zone lymphoma                                    Cases   6,716    100     73      96      193     370     379     476     519     507     632     790     790     876     915     
                                                             CR      0.98     0.21    0.15    0.20    0.40    0.77    0.78    0.98    1.06    1.03    1.28    1.59    1.58    1.75    1.82    
                                                             ASR     0.79     0.20    0.14    0.18    0.35    0.66    0.66    0.81    0.86    0.82    0.99    1.19    1.17    1.25    1.28    18.4^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   B-Cell prolymphocytic leukemia                            Cases   32       0       0       0       0       0       \< 5    0       \< 5    \< 5    \< 5    7       8       5       \< 5    
                                                             CR      0.00     0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.01    0.00    0.01    0.01    0.02    0.01    0.01    
                                                             ASR     0.00     0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.01    0.01    0.01    0.00    6.6
   Hairy cell leukemia                                       Cases   58       \< 5    \< 5    6       \< 5    \< 5    \< 5    \< 5    \< 5    \< 5    6       8       6       6       \< 5    
                                                             CR      0.01     0.01    0.00    0.01    0.00    0.01    0.01    0.01    0.01    0.01    0.01    0.02    0.01    0.01    0.01    
                                                             ASR     0.01     0.01    0.00    0.01    0.00    0.01    0.01    0.01    0.01    0.00    0.01    0.01    0.01    0.01    0.00    3.4
   Plasma cell neoplasms                                     Cases   11,169   466     482     562     560     616     673     791     767     889     913     1,034   1,082   1,062   1,272   
                                                             CR      1.63     0.99    1.01    1.17    1.16    1.28    1.39    1.62    1.57    1.81    1.85    2.08    2.17    2.12    2.53    
                                                             ASR     1.30     0.98    0.99    1.12    1.07    1.14    1.19    1.34    1.26    1.39    1.37    1.48    1.48    1.40    1.63    3.7^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
  **Mature T-cell and NK-cell neoplams**                     Cases   6,612    232     233     265     300     414     441     515     531     503     591     649     654     650     634     
                                                             CR      0.97     0.49    0.49    0.55    0.62    0.86    0.91    1.06    1.09    1.02    1.20    1.31    1.31    1.30    1.26    
                                                             ASR     0.82     0.47    0.46    0.51    0.58    0.77    0.82    0.91    0.92    0.86    0.97    1.05    0.98    0.99    0.95    6.6^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   T lymphoma cutaneous                                      Cases   744      21      22      18      28      34      36      49      57      49      83      89      87      91      80      
                                                             CR      0.11     0.04    0.05    0.04    0.06    0.07    0.07    0.10    0.12    0.10    0.17    0.18    0.17    0.18    0.16    
                                                             ASR     0.09     0.04    0.04    0.04    0.05    0.06    0.07    0.09    0.11    0.08    0.15    0.15    0.14    0.15    0.13    12.5^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Other T and NK- cell lymphomas                            Cases   5,868    211     211     247     272     380     405     466     474     454     508     560     567     559     554     
                                                             CR      0.86     0.45    0.44    0.52    0.57    0.79    0.84    0.96    0.97    0.92    1.03    1.13    1.14    1.12    1.10    
                                                             ASR     0.72     0.42    0.41    0.47    0.53    0.71    0.75    0.81    0.82    0.77    0.83    0.89    0.84    0.84    0.81    5.9^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
  **Precursor cell neoplams**                                Cases   7,409    533     479     521     518     520     480     501     526     536     524     569     581     541     580     
                                                             CR      1.08     1.13    1.01    1.09    1.08    1.08    0.99    1.03    1.08    1.09    1.06    1.15    1.16    1.08    1.15    
                                                             ASR     1.35     1.33    1.19    1.31    1.30    1.31    1.22    1.26    1.35    1.37    1.35    1.46    1.50    1.44    1.50    1.4^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Lymphoblastic lymphoma                                    Cases   749      46      37      52      52      53      58      38      63      45      47      54      66      60      78      
                                                             CR      0.11     0.10    0.08    0.11    0.11    0.11    0.12    0.08    0.13    0.09    0.10    0.11    0.13    0.12    0.15    
                                                             ASR     0.13     0.10    0.09    0.12    0.13    0.12    0.14    0.09    0.15    0.11    0.11    0.14    0.16    0.13    0.18    3.3^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
   Lymphoblastic leukemia                                    Cases   6,660    487     442     469     466     467     422     463     463     491     477     515     515     481     502     
                                                             CR      0.97     1.03    0.93    0.98    0.97    0.97    0.87    0.95    0.95    1.00    0.97    1.04    1.03    0.96    1.00    
                                                             ASR     1.22     1.23    1.10    1.19    1.17    1.19    1.09    1.17    1.21    1.25    1.23    1.33    1.34    1.31    1.32    1.2^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
  **Composite Hodgkin's and non-Hodgkin's lymphoma**         Cases   11       0       \< 5    \< 5    0       0       0       0       0       \< 5    0       \< 5    0       \< 5    \< 5    
                                                             CR      0.00     0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.01    0.00    0.01    0.00    0.00    0.00    
                                                             ASR     0.00     0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    0.00    3.5
  **Unknown type lymphoid neoplasm**                         Cases   6,618    699     668     661     601     455     494     434     431     478     337     339     320     386     315     
                                                             CR      0.97     1.48    1.41    1.38    1.25    0.94    1.02    0.89    0.88    0.97    0.68    0.68    0.64    0.77    0.63    
                                                             ASR     0.80     1.44    1.34    1.29    1.16    0.84    0.90    0.76    0.73    0.77    0.52    0.50    0.46    0.53    0.41    --9.3^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^
  **All lymphoid malignancies**                              Cases   65,948   3,233   3,127   3,490   3,606   3,972   4,282   4,484   4,752   5,047   5,244   5,804   5,956   6,313   6,638   
                                                             CR      9.65     6.85    6.58    7.29    7.49    8.22    8.83    9.21    9.72    10.27   10.61   11.69   11.94   12.60   13.18   
                                                             ASR     8.41     6.89    6.51    7.11    7.21    7.68    8.09    8.17    8.50    8.71    8.80    9.42    9.42    9.74    9.93    3.2^[a)](#tfn1-crt-2017-093){ref-type="table-fn"}^

APC, annual percentage change; CR, crude incidence rate; ASR, age-standardized incidence rate; NK, natural killer.

The annual percent change is statistically different from zero (p \< 0.05).

###### 

Five-year relative survival rates of lymphoid malignancies by age group in Korea

  Site                                                       Age (yr)   Year                                                      
  ---------------------------------------------------------- ---------- -------- ------ -------- ------ -------- ------- -------- ------
  **Hodgkin's lymphoma**                                     Total      473      71.1   649      72.9   862      79.1    1,135    83.0
                                                             0-14       39       87.4   49       94.0   64       95.4    60       91.7
                                                             15-34      167      83.1   226      88.8   306      89.8    420      93.4
                                                             35-49      108      78.5   138      75.2   176      86.4    192      93.3
                                                             50-64      100      53.3   141      58.3   180      74.4    247      80.0
                                                             65-79      55       43.6   87       42.7   118      45.2    189      55.5
                                                             ≥ 80       \< 5     \-     8        \-     18       \-      27       37.0
   Hodgkin's lymphoma, nodular lymphocyte predominant        Total      \< 5     \-     17       \-     17       \-      30       92.5
   Classical Hodgkin's lymphoma                              Total      469      71.0   632      72.8   845      79.0    1,105    82.7
                                                             0-14       39       87.4   49       94.0   64       95.4    59       91.6
                                                             15-34      167      83.1   223      88.7   299      89.6    409      93.2
                                                             35-49      106      78.1   131      73.8   175      86.3    184      93.8
                                                             50-64      98       53.3   136      58.9   173      74.4    239      80.2
                                                             65-79      55       43.6   85       42.4   116      44.8    187      54.5
                                                             ≥ 80       \< 5     \-     8        \-     18       \-      27       37.0
  **Mature B-cell neoplasms**                                Total      4,339    42.8   8,413    47.9   13,590   58.7    19,601   63.8
                                                             0-14       136      67.8   188      81.5   213      79.9    262      87.1
                                                             15-34      495      57.7   704      68.8   996      84.8    1,164    87.6
                                                             35-49      889      54.3   1,702    62.6   2,656    76.1    3,454    81.3
                                                             50-64      1,676    40.3   3,097    47.0   4,602    62.3    6,638    69.9
                                                             65-79      1,057    26.8   2,457    31.7   4,530    41.1    6,930    48.4
                                                             ≥ 80       86       28.4   265      21.1   593      25.2    1,153    29.6
   Chronic lymphocytic leukemia/Small lymphocytic lymphoma   Total      306      53.1   414      53.7   469      63.0    601      73.7
                                                             0-14       14       \-     \< 5     \-     0        \-      \< 5     \-
                                                             15-34      24       \-     15       \-     \< 5     \-      9        \-
                                                             35-49      58       70.4   67       70.0   49       82.7    67       89.2
                                                             50-64      111      57.0   156      58.5   163      67.3    199      88.0
                                                             65-79      89       30.4   146      45.9   225      58.0    277      63.3
                                                             ≥ 80       10       \-     26       6.6    28       41.4    47       45.3
   Immunoproliferative diseases                              Total      40       41.3   60       37.4   94       60.7    153      54.0
   Mantle cell lymphoma                                      Total      40       60.8   118      53.0   237      41.4    355      52.4
                                                             0-14       \< 5     \-     0        \-     0        \-      0        \-
                                                             15-34      5        \-     8        \-     5        \-      \< 5     \-
                                                             35-49      8        \-     22       \-     32       66.6    34       75.7
                                                             50-64      12       \-     53       45.9   91       43.9    138      54.1
                                                             65-79      13       \-     34       45.4   99       27.4    154      49.6
                                                             ≥ 80       \< 5     \-     \< 5     \-     10       \-      27       0.0
   Follicular lymphoma                                       Total      298      64.5   338      71.4   419      79.8    706      88.3
                                                             0-14       7        \-     7        \-     \< 5     \-      \< 5     \-
                                                             15-34      55       69.6   39       85.0   53       100.3   67       93.6
                                                             35-49      80       71.6   103      84.7   117      81.4    207      95.1
                                                             50-64      101      62.2   111      67.5   155      79.8    250      91.0
                                                             65-79      51       57.8   70       49.8   84       63.2    161      74.6
                                                             ≥ 80       \< 5     \-     8        \-     7        \-      17       \-
   Diffuse large B-cell lymphoma                             Total      2,213    49.5   4,413    52.9   6,377    59.1    8,574    61.5
                                                             0-14       60       68.5   82       81.8   69       79.8    88       84.9
                                                             15-34      347      55.4   499      65.6   538      80.6    611      81.5
                                                             35-49      519      57.6   980      63.7   1,303    72.6    1,456    77.6
                                                             50-64      783      49.0   1,532    53.7   2,058    64.2    2,701    70.2
                                                             65-79      461      34.5   1,165    37.1   2,089    43.7    3,116    47.2
                                                             ≥ 80       43       36.5   155      28.8   320      23.0    602      27.1
   Burkitt's lymphoma/Leukemia                               Total      81       52.6   168      66.4   364      57.8    439      62.8
                                                             0-14       47       70.3   90       83.4   126      79.4    155      87.0
                                                             15-34      15       \-     24       \-     72       55.7    73       80.9
                                                             35-49      5        \-     15       \-     49       59.8    81       47.8
                                                             50-64      10       \-     24       \-     77       44.5    66       38.0
                                                             65-79      \< 5     \-     13       \-     36       12.6    58       24.3
                                                             ≥ 80       \< 5     \-     \< 5     \-     \< 5     \-      6        \-
   Marginal zone lymphoma                                    Total      59       90.3   548      85.7   2,165    95.0    3,808    98.2
                                                             0-14       0        \-     \< 5     \-     10       \-      10       \-
                                                             15-34      16       \-     79       92.8   279      97.8    364      99.2
                                                             35-49      15       \-     174      90.2   687      97.9    1,095    99.1
                                                             50-64      21       \-     188      88.2   747      96.6    1,513    97.9
                                                             65-79      7        \-     96       68.9   415      85.0    754      97.7
                                                             ≥ 80       0        \-     7        \-     27       86.5    72       89.3
   B-Cell prolymphocytic leukemia                            Total      0        \-     0        \-     6        \-      25       57.0
   Hairy cell leukemia                                       Total      11       \-     13       \-     16       \-      26       69.8
   Plasma cell neoplasms                                     Total      1,291    20.2   2,341    23.7   3,443    32.6    4,914    36.9
                                                             0-14       \< 5     \-     \< 5     \-     \< 5     \-      \< 5     \-
                                                             15-34      30       57.1   37       62.5   40       85.3    35       82.1
                                                             35-49      194      29.5   326      37.1   401      50.6    498      52.0
                                                             50-64      621      20.2   1,009    25.2   1,275    38.4    1,714    44.2
                                                             65-79      417      12.2   904      16.1   1,538    23.1    2,301    29.5
                                                             ≥ 80       27       22.8   64       6.0    186      11.9    365      18.8
  **Mature T-cell and NK-cell neoplasms**                    Total      442      46.4   1,275    46.4   2,267    44.6    2,979    50.4
                                                             0-14       32       56.4   51       82.4   104      67.4    94       74.8
                                                             15-34      89       56.5   218      57.1   364      60.1    408      74.3
                                                             35-49      126      46.8   322      52.1   554      50.6    667      60.3
                                                             50-64      126      43.0   384      40.1   672      43.1    873      48.4
                                                             65-79      59       32.8   272      34.7   505      26.6    791      32.8
                                                             ≥ 80       10       \-     28       24.5   68       15.1    146      23.4
   T lymphoma cutaneous                                      Total      63       59.8   128      72.6   217      82.5    419      87.7
                                                             0-14       \< 5     \-     7        \-     13       \-      21       \-
                                                             15-34      11       \-     31       77.7   58       88.2    107      95.6
                                                             35-49      21       \-     32       72.7   66       82.8    115      92.7
                                                             50-64      15       \-     30       69.7   49       84.6    95       91.6
                                                             65-79      10       \-     27       64.2   26       61.6    67       69.6
                                                             ≥ 80       \< 5     \-     \< 5     \-     5        \-      14       \-
   Other T and NK-cell lymphomas                             Total      379      44.2   1,147    43.5   2,050    40.5    2,560    44.2
                                                             0-14       29       51.9   44       79.6   91       62.7    73       67.3
                                                             15-34      78       51.6   187      53.7   306      54.8    301      66.7
                                                             35-49      105      46.5   290      49.8   488      46.3    552      53.6
                                                             50-64      111      41.2   354      37.5   623      39.9    778      43.0
                                                             65-79      49       31.7   245      31.5   479      24.6    724      29.4
                                                             ≥ 80       7        \-     27       25.3   63       13.4    132      24.8
  **Precursor cell neoplasms**                               Total      2,111    41.5   2,489    48.7   2,517    52.8    2,691    56.3
                                                             0-14       1,161    61.6   1,286    71.3   1,254    77.8    1,189    82.7
                                                             15-34      524      21.7   618      32.5   563      39.7    595      50.1
                                                             35-49      203      13.0   289      21.0   321      24.6    407      33.0
                                                             50-64      164      9.0    175      15.0   221      15.9    307      20.7
                                                             65-79      57       6.8    113      3.2    142      6.2     174      13.5
                                                             ≥ 80       \< 5     \-     8        \-     16       \-      19       \-
   Lymphoblastic lymphoma                                    Total      101      43.0   222      45.8   249      51.8    294      54.4
                                                             0-14       44       59.2   88       66.0   92       75.1    86       75.2
                                                             15-34      35       31.6   91       36.4   93       47.5    113      54.4
                                                             35-49      11       \-     23       \-     24       \-      48       43.2
                                                             50-64      8        \-     11       \-     28       29.9    23       \-
                                                             65-79      \< 5     \-     9        \-     9        \-      21       \-
                                                             ≥ 80       0        \-     0        \-     \< 5     \-      \< 5     \-
   Lymphoblastic leukemia                                    Total      2,010    41.4   2,267    49.0   2,268    52.9    2,397    56.5
                                                             0-14       1,117    61.7   1,198    71.6   1,162    78.1    1,103    83.3
                                                             15-34      489      21.0   527      31.8   470      38.2    482      49.2
                                                             35-49      192      12.2   266      19.8   297      25.2    359      31.6
                                                             50-64      156      7.4    164      15.3   193      13.9    284      20.9
                                                             65-79      54       7.2    104      2.4    133      6.6     153      11.0
                                                             ≥ 80       \< 5     \-     8        \-     13       \-      16       \-
  **Composite Hodgkin's and non-Hodgkin's lymphoma**         Total      0        \-     \< 5     \-     \< 5     \-      6        \-
  **Unknown type lymphoid neoplasm**                         Total      3,227    47.1   2,957    52.7   1,935    52.1    1,435    50.2
                                                             0-14       168      60.3   124      72.7   69       75.5    27       84.2
                                                             15-34      522      52.8   369      65.6   194      76.5    98       81.4
                                                             35-49      698      58.9   649      67.2   357      70.3    202      78.0
                                                             50-64      1,064    45.6   897      54.5   507      60.7    329      66.2
                                                             65-79      713      31.2   784      32.8   619      33.2    551      35.8
                                                             ≥ 80       62       21.3   134      23.0   189      16.8    228      13.5
  **All lymphoid malignancies**                              Total      10,592   45.3   15,784   49.9   21,173   56.7    27,847   61.7
                                                             0-14       1,536    62.5   1,698    73.5   1,704    78.0    1,632    83.3
                                                             15-34      1,797    48.1   2,135    58.6   2,423    70.6    2,686    78.0
                                                             35-49      2,024    52.6   3,101    59.2   4,066    68.5    4,924    74.8
                                                             50-64      3,130    40.9   4,694    47.0   6,182    58.7    8,394    66.0
                                                             65-79      1,941    28.5   3,713    31.5   5,914    38.2    8,637    45.6
                                                             ≥ 80       164      25.4   443      21.1   884      22.4    1,574    26.6

-, statistic not displayed due to less than 25 cases; NK, natural killer.

###### 

International comparison of age-standardized incidence rates of lymphoid malignancies

                    Europe (HAEMACARE)^[a)](#tfn2-crt-2017-093){ref-type="table-fn"}^   The United States (SEER White)^[b)](#tfn3-crt-2017-093){ref-type="table-fn"}^   The United States (SEER Asian)^[b)](#tfn3-crt-2017-093){ref-type="table-fn"}^   Hong Kong^[b)](#tfn3-crt-2017-093){ref-type="table-fn"}^   Japan^[c)](#tfn4-crt-2017-093){ref-type="table-fn"}^   KCCR^[d)](#tfn5-crt-2017-093){ref-type="table-fn"}^
  ----------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------ -----------------------------------------------------
  HL                2.41                                                                2.91                                                                            1.28                                                                            0.75                                                       0.5                                                    0.35
  CLL/SLL           3.79                                                                4.75                                                                            1.06                                                                            0.52                                                       0.1                                                    0.18
  DLBCL             3.13                                                                5.59                                                                            4.37                                                                            3.26                                                       2.5                                                    2.34
  FL                1.92                                                                3.17                                                                            1.33                                                                            0.75                                                       0.1                                                    0.18
  MCL               NA                                                                  0.63                                                                            0.24                                                                            0.20                                                       0.1                                                    0.09
  MZL               NA                                                                  1.53                                                                            1.18                                                                            0.74                                                       0.5                                                    0.79
  BL                NA                                                                  0.42                                                                            0.28                                                                            0.27                                                       0.12                                                   0.16
  PCN               4.62                                                                4.03                                                                            2.54                                                                            1.99                                                       1.5                                                    1.30
  Extranodal NK/T   NA                                                                  0.06                                                                            0.12                                                                            0.25                                                       0.08                                                   0.22
  ALCL              NA                                                                  0.32                                                                            0.20                                                                            0.18                                                       0.11                                                   0.11
  AITL              NA                                                                  0.10                                                                            0.13                                                                            0.12                                                       0.12                                                   0.10
  PTCL-NOS          NA                                                                  0.30                                                                            0.28                                                                            0.27                                                       0.25                                                   0.26
  ALL/LBL           1.42^[e)](#tfn6-crt-2017-093){ref-type="table-fn"}^                 1.7^[f)](#tfn7-crt-2017-093){ref-type="table-fn"}^                              NA                                                                              1.1                                                        1.22                                                   
  All lymphoid      24.50                                                               28.55                                                                           16.11                                                                           11.22                                                      NA                                                     8.41

All rates expressed per 100,000 person-years. SEER, Surveillance, Epidemiology, and End Results; KCCR, Korea Central Cancer Registry; HL, Hodgkin's lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; NA, not available; MZL, marginal zone lymphoma; BL, Burkitt's lymphoma/leukemia; PCN, plasma cell neoplasm; NK, natural killer; ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; ALL, acute lymphoblastic leukemia; LBL, lymphoblastic lymphoma.

Data from European HAEMACARE project \[[@b10-crt-2017-093]\],

Ageadjusted to the World Health Organization's World Standard Population (2000-2025) \[[@b21-crt-2017-093]\],

Age-standardized to the world population. Estimated values from the published figures \[[@b22-crt-2017-093]\],

Weighted averages of crude age-specific rates, calculated using Segi's world standard population (presented data),

This rate includes lymphoblastic lymphomas,

From SEER data including all ethnic groups. Age-adjusted to the 2,000 U.S. standard population \[[@b23-crt-2017-093]\].
